Biomedical Occupation or Discipline
Valo Health Suspends Development of OPL-0401, a ROCK Inhibitor for Diabetic Retinopathy, Following Phase 2 Study Results
Valo Health, OPL-0401, ROCK Inhibitor, Diabetic Retinopathy, Phase 2 Study, Clinical Trials, Drug Development
FDA Approves Humacyte’s Symvess: A Revolutionary Off-the-Shelf Artery Implant for Vascular Trauma Repair
FDA Approval, Humacyte, Symvess, Vascular Trauma, Off-the-Shelf Artery Implant, Bioengineered Human Tissue, Extremity Vascular Trauma Treatment
Biopharmaceutical Manufacturing and Emerging Trends in 2024: A Global Outlook
Biopharmaceutical manufacturing, 2024 trends, personalized medicine, AI-driven drug discovery, biosimilars, cell and gene therapies, biotechnology innovations.
FDA Approves Humacyte’s Symvess ATEV: A Breakthrough in Regenerative Medicine for Vascular Trauma Treatment
Humacyte, FDA approval, Symvess ATEV, regenerative medicine, vascular trauma, lab-grown blood vessels
KdT Ventures Launches New Biotech Startup to Develop NGM Bio’s Rare Disease Drug Candidate NGM313
KdT Ventures, NGM Bio, NGM313, Rare Disease, Biotechnology, Drug Development, Phase 2 Trial
Novartis and BioAge Collaborate on Longevity and Exercise Targets for Age-Related Diseases
Novartis, BioAge Labs, Longevity, Exercise Biology, Age-Related Diseases, Therapeutic Targets, Human Longevity Data, Research Collaboration
Aurion Biotech Advances to Phase III Trials with Promising Allogeneic Cell Therapy for Corneal Oedema
Allogeneic cell therapy, Corneal oedema, Corneal endothelial dysfunction, AURN001, Phase III clinical trials, Vision restoration, Biotechnology, Clinical development
Biopharma’s New Horizon: Industry Leaders Converge at JPM 2025
JPM 2025, Biopharma, Jennifer Doudna, Janet Woodcock, Robert Nelsen, Scott Gottlieb, Healthcare, Gene Editing, CRISPR, Pharmaceutical Industry, Biotechnology
Aurion Biotech’s AURN001 Shows Significant Vision Improvement in Phase 1/2 Trial for Corneal Edema
AURN001, corneal edema, corneal endothelial dysfunction, allogeneic cell therapy, regenerative medicine, clinical trial results
Candid Therapeutics Expands T-Cell Engager Pipeline with Strategic Collaborations
T-cell engagers, autoimmune diseases, biotechnology, Candid Therapeutics, collaborations, EpimAb Biotherapeutics, Nona Biosciences